Oceanía · Bolsa y Finanzas · Stockhead

Health Check: CSL places $500m-plus bet on rare kidney and liver disease drug candidate

Publicado por Stockhead · Australia hace 2 h

CSL will pay an upfront US$355 million ($515m) to co-develop an external drug candidate aimed at treating rare kidney and ... Read More The post Health Check: CSL places…

Leer el artículo completo en Stockhead Inicie sesión para guardar

MediaNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (stockhead.com.au)

Health Check: CSL places $500m-plus bet on rare kidney and liver disease drug candidate

También te puede interesar

Orbital inks second Indian drone propulsion deal

Has AI Reset the Cycle?

The Trust Trap: why tighter control can hurt a growing business

Property downturn worsens with less than 50pc of auctions leading to a sale

Pavlova hits the Big Apple as Gelato Messina makes New York debut

Fulton Hogan revenues and profits rebound after 2025 downturn

Health Check: CSL places $500m-plus bet on rare kidney and liver disease drug candidate

Compartir

También te puede interesar

Orbital inks second Indian drone propulsion deal

Has AI Reset the Cycle?

The Trust Trap: why tighter control can hurt a growing business

Property downturn worsens with less than 50pc of auctions leading to a sale

Pavlova hits the Big Apple as Gelato Messina makes New York debut

Fulton Hogan revenues and profits rebound after 2025 downturn